Oxford BioMedica PLC

142 articles with Oxford BioMedica PLC

• Oxford BioMedica Forges A $100 Million+ CAR-T Supply Deal With Novartis AG

  7/7/2017

• Oxford BioMedica PLC Notes Findings On CTL019 From Phase II JULIET Study Presented At The 14th Meeting Of International Conference On Malignant Lymphoma (ICML)

  6/15/2017

• Orchard Therapeutics Announces Strategic Alliance With Oxford BioMedica PLC

  11/29/2016

• Oxford BioMedica PLC Announces Expanded Collaboration And Licence With Immune Design Corporation

  3/7/2016

• Oxford BioMedica PLC Release: Interim Results For The Six Months Ended 30 June 2015

  8/27/2015

• Oxford BioMedica PLC Interim Management Statement

  5/7/2015

• Oxford BioMedica PLC Appoints Daniel Soland As Non-Executive Director To The Board

  5/7/2015

• Oxford BioMedica PLC Announces That A Summary Of The 12 Month And Three Year Follow Up Data From The Phase I/II Study With Prosavin Was Presented At The AANS Conference In The U.S.

  5/5/2015

• Oxford BioMedica PLC Secures $50 Million

  5/1/2015

• Oxford BioMedica PLC To Present at 3rd Annual Regen Med Investor Day

  3/20/2015

• Oxford BioMedica PLC Director's Share Purchase

  3/16/2015

• Oxford BioMedica PLC: Preliminary Results For The Year Ended 31 December 2014

  3/13/2015

• Oxford BioMedica PLC: Notice of Preliminary Results

  3/6/2015

• Oxford BioMedica PLC Announces Presentation At 27th Annual ROTH Conference

  3/5/2015

• Chief Secretary To The Treasury Visits Oxford BioMedica PLC

  2/23/2015

• Oxford BioMedica PLC Interim Management Statement

  11/3/2014

• Oxford BioMedica PLC Director's Share Purchase

  10/14/2014

• Oxford BioMedica PLC Acquires Windrush Court Office And Laboratory Facilities

  10/13/2014

• Oxford BioMedica PLC Inks Transformational $90 Million Deal With Novartis AG

  10/10/2014

• Oxford BioMedica PLC Interim Results For The Six Months Ended 30 June 2014

  8/28/2014